Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fuji Pharma, M3 Join Hands on Dysmenorrhea Med in Japan
November 13, 2020
- Voluntary Recalls Launched for Pfizer/MSD’s Antidepressant Trazodone
November 13, 2020
- Sagent Launches US PII to Test Camostat Mesilate for COVID-19
November 13, 2020
- Humira’s Pediatric Dosage Filed for Ulcerative Colitis in Japan: AbbVie
November 13, 2020
- Osaka Univ. Spin-Off Boots Up to Develop First Treatment for Skeletal Muscle Damage, Atrophy
November 13, 2020
- PeptiDream, 4 Other Firms Establish JV to Develop COVID-19 Therapeutics
November 13, 2020
- Ex-Daiichi Sankyo Chairman Kiyoshi Morita Dies at 81
November 13, 2020
- Fujifilm Grants Rights to Patent on iPS Cell Generation to Lonza
November 13, 2020
- Taiho Obtains Japan Rights for US Firm’s Loculated Pleural Effusion Med
November 13, 2020
- AstraZeneca Launches Healthcare Innovation Hub in Japan
November 12, 2020
- Nippon Kayaku’s Biosimilar Sales to Hit 10 Billion Yen Mark in Full-Year, Trastuzumab Upbeat
November 12, 2020
- Roche Diagnostics Rolls Out COVID-19 Antibody Detection Reagent in Japan for Research Use
November 12, 2020
- New BMS to Rev Up Open Innovation Drive in Japan, Evolve Portfolio in 6 Focus Areas: Country CEO
November 12, 2020
- Medicago’s COVID-19 Vaccine Shows Positive PI Results, Now Gearing Up for PII, PIII Studies
November 12, 2020
- Nichi-Iko Recalls 7 More Products, Critical Eyes from Healthcare Professionals
November 11, 2020
- Lenvima Plus Keytruda Yield Positive Data in 1st Line RCC
November 11, 2020
- AnGes to Buy US Gene Editing Therapeutics Firm Emendo
November 10, 2020
- Incyte Gearing Up for Solo Marketing in Japan, Set to Double Workforce to 70 Staffers
November 10, 2020
- Ono/BMS Sign Patent License Deal for Tecentriq with Roche
November 10, 2020
- Japan Ethical Drug Sales Drop 9.6% in September: Crecon
November 10, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…